PeerJ
Screening for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes patients using the fibrosis-4 score in medina-retrospective study
By Almohammadi MA, Alsadi ZE, Alenezi AB and 7 others.
Abstract
Background
Type 2 diabetes mellitus (T2DM) is a global health problem closely linked to metabolic dysfunction-associated steatotic liver disease (MASLD) and advanced fibrosis. The fibrosis-4 (FIB-4) index is a standard noninvasive tool for estimating fibrosis risk. This study aimed to describe the demographics, metabolic parameters, comorbidities, and T2DM duration of patients in Medina and to screen for MASLD using the FIB-4 score.
Methods
At King Salman Diabetic Center, Medina, Saudi Arabia, a cross-sectional study was conducted among 280 T2DM patients aged >35 years. Data were gathered from electronic medical records. FIB-4 levels were calculated and categorized as low (<1.3), intermediate (1.3-2.67), or high (>2.67) risk. Statistical analysis was performed with IBM SPSS Statistics 30, with p < 0.05 considered significant.